Gwynn Douglas Long

Gwynn Douglas Long

Professor of Medicine

Overview

1. High dose therapy and autologous and allogeneic stem cell rescue for hematologic malignancies (especially multiple myeloma) and solid tumors.
2. Non-myeloablative allogeneic transplants for hematologic malignancies and solid tumors.
3. Supportive care for hematopoietic stem cell transplants.
4. Prevention and therapy of graft versus host disease.

Positions

Professor of Medicine in the School of Medicine

2021 School of Medicine

Education

M.S., Wake Forest University 1979

1979 Wake Forest University

M.D., Wake Forest University 1983

1983 Wake Forest University

Medical Resident, Vanderbilt University, Medicine 1983 - 1986

1986 Vanderbilt University

Fellow in Medical Oncology, Stanford University, Medicine 1987 - 1990

1990 Stanford University

Publications, Grants & Awards

Grants (5)
Academics Articles (117)
Conference Pages (2)

2020-2028Immune Tolerance Network

2021-2025Benaroya Research Institute at Virginia Mason

An Open-label Pilot Multicenter Study to Evaluate the Safety and Efficacy of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms

2020-2025ADC Therapeutics Sarl

A Phase I Open Label Study of Panobinostat in combination with Lenalidomide, Bortezomib, and Dexamethasone in patients with relapsed and relapsed/refractory Multiple Myeloma

2014-2023Dana-Farber/Partners CancerCare, Inc.

A Randomized, Dbl-Blind, Placebo-Controlled, Parallel-Grp, Multictr, Ph 3 Study-Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients

2013-2016Chimerix, Inc.

DCI Centers, Cancer Types & Labs

Hematologic Malignancies and Cellular Therapy

Offices & Contact

Cellular Therapy ABMT
Durham, NC
27705

Box 3961 Med Ctr
Durham, NC
27710